Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: costeffectiveness analyses and implications for The Netherlands
| Autor: | Marie-Louise A. Heijnen, Johannes C Jager, Maarten J. Postma, Philippe Beutels |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Cost effectiveness Cost-Benefit Analysis Immunology Pneumococcal Infections Pneumococcal Vaccines Pharmacoeconomics Drug Discovery medicine Humans Intensive care medicine health care economics and organizations Aged Netherlands Pharmacology Invasive disease business.industry Vaccination Vaccine efficacy medicine.disease Pneumococcal infections Pneumococcal vaccine Pneumococcal vaccination Molecular Medicine business |
| Zdroj: | Expert Review of Vaccines. 2:477-482 |
| ISSN: | 1744-8395 1476-0584 |
| DOI: | 10.1586/14760584.2.4.477 |
| Popis: | We performed a review of cost-effectiveness of elderly pneumococcal vaccination to prevent invasive disease. It concerns studies in the USA, Canada, Netherlands and Spain and a multinational study of five European countries. Cost-effectiveness of elderly vaccination against invasive pneumococcal infections varies from cost-saving to EUR 33,000 per life-year gained. The Dutch study estimates cost-effectiveness at EUR 10,100 per life-year gained (price level: 1995). This is below the level that has recently been defined for treatment of high cholesterol (EUR 20,000 per life-year gained) and may therefore be considered as favorable. Almost all studies base their estimate of vaccine efficacy on the same case-control study from the USA. We identify a need for a systematic review on the efficacy of the pneumococcal vaccine. Also, we suggest further analysis with respect to potential effects on cost-effectiveness of extended influenza vaccination for the Dutch elderly in recent years and inclusion of pneumococcal re-vaccination. Pending this additional information, we conclude that cost-effectiveness of vaccination against invasive pneumococcal infections for Dutch elderly is favorable (as in several other countries) and justifies implementation from a pharmacoeconomic point of view. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|